Neurofibromatosis type 1 with diagnostic value of skin and ocular manifestations
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20251436Keywords:
Neurofibromatosis type 1, Neurofibromin, Autosomal dominant, Genetic mutation, Café-au-lait macules, Lisch nodules, Axillary frecklingAbstract
Neurofibromatosis type 1 (NF1) is a genetic mutation - autosomal dominant neurocutaneous condition, with variable clinical expression. The mutation in a gene contains the code for making a protein (Neurofibromin), which acts as tumor suppressor. It is characterized by a pigmentation of skin, non-cancerous (benign) tumors to grow along the nerves in skin, eyes, brain and other body parts. Those tumors and their complications are usually causing a range of symptoms. It is an extremely variable multisystem disease; the progression and severity may differ throughout life in an affected individual as well as in affected family members with the same NF1. This case report presents a 12-year-old boy with a clinical diagnosis of NF1, who was diagnosed initially at the age of two with multiple hyperpigmented macules. He has a positive family history, with similar symptoms in his father and grandfather. Dermatological examination revealed café-au-lait macules (CALMs) on the chest and back, measuring over 1.5 cm, alongside axillary and inguinal freckling. Ophthalmological evaluation showed Lisch nodules in both irises and iris hyperpigmentation. Previous lab tests were normal, and imaging studies, including eyes ultrasounds and brain MRI, revealed no abnormalities. This case illustrates the importance of early cutaneous and ocular findings in the diagnosis of NF1, also Multidisciplinary follow ups are important to detect early systemic complications.
Metrics
References
Accetturo M, Bartolomeo N, Stella A. In-silico analysis of NF1 missense variants in Clinvar: translating variant predictions into variant interpretation and classification. Int J Mol Sci. 2020;21(3):721. DOI: https://doi.org/10.3390/ijms21030721
Albaghdadi M, Thibodeau ML, Lara-Corrales I. Updated approach to patients with multiple café au lait macules. Dermatol Clin. 2022;40(1):9-23. DOI: https://doi.org/10.1016/j.det.2021.08.002
Al-Farsi FAH, Al-Alyani OBS, Al-Kumzari A, Al-Saadi T. Systemic review and meta-analysis of the intellectual integrity of children with neurofibromatosis type 1. World Neurosurg. 2022;157:69-74. DOI: https://doi.org/10.1016/j.wneu.2021.10.081
Anderson MK, Johnson M, Thornburg L, Halford Z. A review of selumetinib in the treatment of neurofibromatosis type 1-related plexiform neurofibromas. Ann Pharmacother. 2022;56(6):716-26. DOI: https://doi.org/10.1177/10600280211046298
Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004;17(2):101-5. DOI: https://doi.org/10.1097/00019052-200404000-00004
Riccardi VM. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 2nd ed, Johns Hopkins University Press; 1992. DOI: https://doi.org/10.1097/00005072-199211000-00009
Huson SM, Hughes RAC, Harper PS. Clinical presentation of neurofibromatosis type 1 in children and adolescents. Brain. 1989;112(5):1083-91.
Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1994;125(1):63-6. DOI: https://doi.org/10.1016/S0022-3476(94)70122-9
Ferner RE, Huson SM, Thomas N, Celia M, Harry W, Gareth DE, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81-8. DOI: https://doi.org/10.1136/jmg.2006.045906
Barnett C, Alon T, Abraham A, Kim RH, McCuaig JM, Kongkham P, et al. Evidence of small-fiber neuropathy in neurofibromatosis type 1. Muscle Nerve. 2019;60(6):673-8. DOI: https://doi.org/10.1002/mus.26687